Hearing changes after radiotherapy and chemotherapy for head and neck cancer
Looks at hearing before and after cancer treatment in adults with head and neck tumours.
Key facts
- Who runs it
- University of Manchester
- Where
- Manchester, United KingdomSee the site
- Trial code
- Registry title
- The Effects on Auditory Function of RADiotherapy and Chemotherapy Treatments for Head and Neck Tumours (EARAD)
- Status
- Recruiting
- People taking part
- 100 people, planned
- Started
- 1 May 2019
- Expected to end
- Dec 2026
- Type of study
- Observational, 7 groups
- Record updated
- 8 May 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with head and neck cancer who will have, or had, radiotherapy with or without cisplatin chemotherapy. It studies effects on hearing. It also takes control people with normal hearing or with hearing loss.
- Age
- 18 years and older.
- Sex
- All sexes can join.
- Disease stage
- Head and neck cancer. Past-treatment group: radiotherapy to one side of the head, within 5 years after treatment.
- Earlier treatment
- The care team has decided on radiotherapy, with or without cisplatin-based chemotherapy. People planned for carboplatin-based chemotherapy cannot join.
- Biomarker or test result
- Hearing tests: new patients cannot have hearing loss greater than 25 dB HL (average from 0.25 to 4 kHz). Normal-hearing controls: no loss greater than 20 dB HL. Hearing-impaired controls: loss greater than 20 dB HL.
Main reasons for not taking part
- New patients with hearing loss greater than 25 dB HL before the study
- New patients who already need a hearing aid
- Treatment plan with carboplatin-based chemotherapy
- Taking part in another study with a treatment known to harm hearing
- Unable to give informed consent
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Diagnosed with head and neck cancer
- An MDT treatment decision of radiotherapy +/- cisplatin based chemotherapy
- Previously diagnosed and treated for head and neck cancer
- Radiotherapy treatment to one side of the head
- Within 5 years post-treatment
- An MDT treatment decision of radiotherapy +/- cisplatin based chemotherapy
- Hearing loss greater than 20 dB HL (average from 0.25 to 4 kHz)
Who cannot take part
- Hearing loss greater than 25 dB HL (average from 0.25 to 4 kHz) prior to the study
- An MDT treatment decision of carboplatin based chemotherapy
- An MDT treatment decision of carboplatin based chemotherapy
- Existing hearing loss (self-reported- need for hearing aid)
- Involved in another research project where the treatment is known to be ototoxic
- Unable to give informed consent; For Retrospective Patient Cohort:
- Unable to give informed consent; For Retrospective Normal-Hearing Controls:
- Hearing loss greater than 20 dB HL (at any octave frequency from 0.25 to 4 kHz)
- Unable to give informed consent; For Retrospective Hearing-Impaired Controls:
- Unable to give informed consent
Other criteria
- For Prospective Patient Cohorts:
Where in United Kingdom
- The Christie NHS Foundation TrustManchester, United KingdomContact: Rachael WildingTaking people
About the trial
What the trial wants to find out
Radiotherapy and combined radiotherapy and chemotherapy are used to treat most tumours in the head and neck region. Unfortunately, these treatments often result in hearing loss and tinnitus that has a negative impact on quality of life. This study will use a battery of sensitive tests, including measures of hair cell and neural function, before and after treatment, to measure the effects of these treatments on auditory function. The results will be compared with the individual radiotherapy dose characteristics, using state-of-the-art data mining technology, to identify the auditory substructures that are most sensitive to radiation with respect to the effects on auditory function. The data will provide the basis for new dose constraints to limit radiation doses to any identified substructures and to minimise loss in hearing ability for patients undergoing treatment for head and neck cancer.
The 7 groups in the trial
- Discovery Phase - Radiotherapy only
25 patients undergoing radiotherapy only for head / neck cancer
- Discovery Phase - Radiotherapy plus chemotherapy
25 patients undergoing radiotherapy plus chemotherapy for head / neck cancer
- Validation Phase - Radiotherapy only
25 patients undergoing radiotherapy only for head / neck cancer
- Validation Phase - Radiotherapy plus chemotherapy
25 patients undergoing radiotherapy plus chemotherapy for head / neck cancer
- Retrospective Cohort
50 patients who previously received unilateral radiotherapy for head / neck cancer up to 5 years post-treatment
- Normal Hearing Controls for Retrospective Cohort
50 controls with normal hearing, age- and sex-matched to retrospective cohort
- Hearing Impaired Controls for Retrospective Cohort
50 controls with impaired hearing, age-, sex-, and audiogram-matched to retrospective cohort
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The Effects on Auditory Function of RADiotherapy and Chemotherapy Treatments for Head and Neck Tumours (EARAD)
- Plain-language title
- Hearing changes after radiotherapy and chemotherapy for head and neck cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 8 May 2024